Toronto (Canada) – Fasken was recognized across inthe 2024-2025 edition of Lexpert’s Top 10 Business Decisions™ highlighting our legal talent. The list is based on an assessment of the most significant Canadian legal cases with decisions released between Oct. 1, 2024, and Sept. 30, 2025.
Of the top ten 10 cases recognized, the Firm acted on the following:
In Sanis Health Inc v. British Columbia, 2024 SCC 40, the Fasken team was led by Peter J. Pliszka, Andrew Borrell, and Tom Posyniak, who represent Sandoz Health Inc., in defence of a national class action by the provincial and federal governments of Canada against several opioid manufacturers and distributors. Sandoz Canada Inc. is a Canadian pharmaceutical manufacturer that produces and distributes generic and biosimilar medicines.
Fasken’s Life Sciences Group stands out as a leading force in Canada. We are called upon at every stage of our clients’ product life cycle, from early stages of development and commercialization through to consumer use and legal proceedings. Our team includes lawyers with advance degrees in pharmaceutical sciences, clinical pharmacology, toxicology and genetics, with a vast network of life sciences experts in 47 countries across the globe. We are committed to leadership in life sciences law; we wrote the leading guide to legal and regulatory regimes governing the manufacture and sale of drugs, medical devices and cosmetics in Canada, and we conduct frequent presentations to clients and industry organizations and associations. We work collaboratively to solve significant legal issues that demand creative approaches and robust strategic advocacy. Renowned for our pragmatic and results-oriented advice, we are trusted to guide our clients to successful outcomes.